Ophthalmic Drugs & Devices Market Size, Share, Analysis 2031

Ophthalmic Drugs & Devices Market Size, Share, Analysis 2031

Segments - Canada Ophthalmic Drugs & Devices Market by Products (Drugs [Dry Eye Drugs, Glaucoma Drugs, Allergic Conjunctivitis and Inflammation Drugs, Retinal Disorder Drugs, and Other Drugs] and Devices [Diagnostic Devices and Surgical Devices]), Diseases (Refractive Disorders, Cataract, Inflammatory Diseases, Glaucoma, Age-related Degeneration, and Other Diseases) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-1092 | 4.8 Rating | 69 Reviews | 145 Pages | Format : PDF Excel PPT

Report Description


The Canada ophthalmic drugs & devices market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 6.6% during 2023–2031. The growth of the market is attributed to innovations and advancements in the technologies and growing awareness about the eye-related diseases. Developing technologies of devices for the diseases is expected to drive the market.

Ophthalmology is a branch of medicine that deals with the treatment, body structure, anatomy, and diagnosis of the eye disorders. Specialist in clinical and surgical eye issues is known as ophthalmologist who carries operations on eyes. The ophthalmic devices are used in various applications such as glaucoma surgery, cataract surgery, and refractive surgery with the help of various technologies.

Canada Ophthalmic Drugs & Devices Market Outlook

Ophthalmic drugs are used for the treatment of various eye diseases including cataract, eye infection, inflammatory diseases, and glaucoma, and detect various ocular malformations in the eyes.

The main cause of visual impairment in Canada is cataract, diabetic retinopathy, glaucoma, age related macular degeneration, and degenerative myopia. The prevalence of age related macular degeneration was around 18,644 in 2018 and 19,252 in 2019, according to Global Health Data Exchange. The growing prevalence is anticipated to boost the Canada ophthalmic drugs & devices market.

  • Technological innovation in drug delivery system is estimated to propel the market during the forecast period.

  • Increasing aging population in Canada is anticipated to push the market in the coming years.

  • Rapid growth of hospital infrastructure is key factor spurring the market during the forecast period.

  • Increasing prevalence of diseases related to eye is major factor fueling the market in the coming years.

  • Growing provenance of eye disorder is major factor boosting the market.

  • Lack of awareness about diseases related eye disorders act as major challenge that can restrict the market growth.

  • Lack of knowledge about health related policies and insurance act as key factor that can impede the market expansion.

  • R&D investment and technological advancement and innovation are estimated to offer lucrative opportunities for the market players.

Scope of Canada Ophthalmic Drugs & Devices Market Report

The report on the Canada ophthalmic drugs & devices market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Ophthalmic Drugs & Devices Market - Canada Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Products (Drugs [Dry Eye Drugs, Glaucoma Drugs, Allergic Conjunctivitis and Inflammation Drugs, Retinal Disorder Drugs, and Other Drugs] and Devices [Diagnostic Devices and Surgical Devices]) and Diseases (Refractive Disorders, Cataract, Inflammatory Diseases, Glaucoma, Age-related Degeneration, and Other Diseases)

Country

Canada

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Carl Zeiss Meditec AG, Alcon Inc., Nidek Co. Ltd, Bausch Health Companies Inc., and Johnson & Johnson

Canada Ophthalmic Drugs & Devices Market Segment Insights

The retinal disorder drugs and diagnostics devices segment is projected to hold a key market share

Based on product, the Canada ophthalmic drugs & devices market is divided into drugs and devices. The drugs segment is further segregated into dry eye drugs, glaucoma drugs, allergic conjunctivitis and inflammation drugs, retinal disorder drugs, and other drugs. The devices segment is further classified into diagnostic devices and surgical devices.

The retinal disorder drugs segment is expected to represent a key share of the market in the coming years owing to increasing retinal disorder diseases in the region. Availability of the retinal disorder drugs and rising sales of the drugs is projected to boost the Canada ophthalmic drugs & devices market.


On the other hand, the diagnostic devices segment is expected to constitute a key share of the market during the forecast period due to rising infectious diseases and increasing demand from the hospitals and clinics is fueling the market.

The cataract segment is projected to account for large market share

In terms of diseases, the Canada ophthalmic drugs & devices market is fragmented into refractive disorders, cataract, inflammatory diseases, glaucoma, age-related degeneration, and other diseases.

The cataract segment is expected to represent a key share of the market during the forecast period due to growing burden of eye diseases in Canada. The advanced technology, innovation of eye drops for the cataract diseases is anticipated to boost the market in the coming years. The rising covid-19 and related eye diseases is estimated to fuel the market for cataract diseases segment.

Canada Ophthalmic Drugs & Devices Market Diseases

Segments

The Canada ophthalmic drugs & devices market has been segmented on the basis of

Product

  • Drugs
    • Dry Eye Drugs
    • Glaucoma Drugs
    • Allergic Conjunctivitis and Inflammation Drugs
    • Retinal Disorder Drugs
    • Other Drugs
  • Devices
    • Diagnostic Devices
    • Surgical Devices

Diseases

  • Refractive Disorders
  • Cataract
  • Inflammatory Diseases
  • Glaucoma
  • Age-related Degeneration
  • Other Diseases

Key Players

Competitive Landscape

Key players competing in the Canada ophthalmic drugs & devices market include Carl Zeiss Meditec AG, Alcon Inc., Nidek Co. Ltd, Bausch Health Companies Inc., and Johnson & Johnson. Many key players are currently dominating the Canada ophthalmic drugs & devices market. Some of these players are focusing on several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

Canada Ophthalmic Drugs & Devices Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ophthalmic Drugs & Devices Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Ophthalmic Drugs & Devices Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Ophthalmic Drugs & Devices Market - Supply Chain
  4.5. Global Ophthalmic Drugs & Devices Market Forecast
     4.5.1. Ophthalmic Drugs & Devices Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Ophthalmic Drugs & Devices Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Ophthalmic Drugs & Devices Market Absolute $ Opportunity
5. Global Ophthalmic Drugs & Devices Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Ophthalmic Drugs & Devices Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Ophthalmic Drugs & Devices Demand Share Forecast, 2019-2026
6. North America Ophthalmic Drugs & Devices Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Ophthalmic Drugs & Devices Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Ophthalmic Drugs & Devices Demand Share Forecast, 2019-2026
7. Latin America Ophthalmic Drugs & Devices Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Ophthalmic Drugs & Devices Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Ophthalmic Drugs & Devices Demand Share Forecast, 2019-2026
8. Europe Ophthalmic Drugs & Devices Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Ophthalmic Drugs & Devices Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Ophthalmic Drugs & Devices Demand Share Forecast, 2019-2026
9. Asia Pacific Ophthalmic Drugs & Devices Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Ophthalmic Drugs & Devices Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Ophthalmic Drugs & Devices Demand Share Forecast, 2019-2026
10. Middle East & Africa Ophthalmic Drugs & Devices Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Ophthalmic Drugs & Devices Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Ophthalmic Drugs & Devices Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Ophthalmic Drugs & Devices Market: Market Share Analysis
  11.2. Ophthalmic Drugs & Devices Distributors and Customers
  11.3. Ophthalmic Drugs & Devices Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Carl Zeiss Meditec AG Alcon Inc. Nidek Co. Ltd Bausch Health Companies Inc. Johnson & Johnson

Methodology

Our Clients

Microsoft
Dassault Aviation
FedEx Logistics
Honda Motor Co. Ltd.
General Electric
Nestle SA
Deloitte
sinopec